GLP-1 drugs, or GLP-1 receptor agonists (think Ozempic), initially approved in 2005 for treatment of type 2 diabetes, have recently seen explosive use in the general population, primarily as weight loss aids. The Ozempic boom is highly visible in the media and in pharmaceutical company advertising, exacerbating the overuse of GLP -1RA class drugs. The seduction is real: Lose weight with less effort, look and feel your best, and reduce the risk of obesity-related health concer